Image

Global Liposomal Doxorubicin Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Liposomal Doxorubicin Market, By Drug Formulation (Lyophilized Powder and Doxorubicin Injection), by Application (Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Others), Product (Doxil, Lipodox, Myocet, Others), Type (Anthracycline Antibiotic, Others), Route of Administration (Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Liposomal doxorubicin Market

Liposomal doxorubicin Market Analysis and Size

Liposomal doxorubicin is in huge demand because of its application in treating cancer, Kaposi sarcoma, and several other illnesses. Sales of liposomal doxorubicin are expected to grow after the dysfunctioning of earlier systemic treatment for ovarian cancer and other AIDS-related Kaposi's sarcoma. The market size is increasing as people become more aware of the numerous cancer treatment options . Innovations enable site-specific drug delivery and regulated drug release in the body.

Data Bridge Market Research analyses a growth rate in the liposomal doxorubicin market  in the forecast period 2023-2030. The expected CAGR of liposomal doxorubicin market  is tend to be around 5.90% in the mentioned forecast period. The market was valued at USD 1240 million in 2022, and it would grow upto USD 1961.50 million by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Liposomal doxorubicin Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug Formulation (Lyophilized Powder and Doxorubicin Injection), by Application (Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Others), Product (Doxil, Lipodox, Myocet, Others), Type (Anthracycline Antibiotic, Others), Route of Administration (Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Johnson & Johnson Services, Inc.(U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Cipla Inc. (India), Lupin (India), Cadila Pharmaceuticals (India) and SRS Life Sciences (India), Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd (China)

Market Opportunities

  • ncreasing Demand of J&J (Doxil/Caelyx)
  • Increasing Product Launches

Market Definition

Doxorubicin (liposomal) is used to treat breast cancer, AIDS related Kaposi sarcoma, ovarian cancer and other cancerous tumours. Doxorubicin is an anti-cancer chemotherapy drug encapsulated in a closed lipid sphere called liposome. This medicine is classified as an "anthracycline antibiotic." It is given by injection through a vein (intravenously, by IV). Doxorubicin (liposomal) is an irritant. 

Global Liposomal doxorubicin Market Dynamics

Drivers

  • Increased Awareness About Cancer Therapies

Numerous government programs aimed at raising awareness and providing new cancer therapy methods have increased the demand for liposomal doxorubicin and are likely to increase more  during the forecast period. For instance, in 2020, the National Comprehensive Cancer Control Program, that provides guidance, funding, and technical assistance to help programs in implementing cancer prevention and control plans, may surge the market opportunities for major market players to launch new products into the market

  • Rising Prevalence of Breast Cancer

According to the International Agency for Research on Cancer (IARC) in December 2020, 1 in 4 cancer diagnoses in women globally is breast cancer cases. As per the records of WHO, there were around 2.3 million women diagnosed with breast cancer in the year 2020, and there were almost 685,000 deaths worldwide. Breast cancer was the most common cancer in the world in 2020, with 7.8 million women having received a diagnosis in the last five years. Thus, this prevalence is demanding more growth of these drugs.

Opportunities

  • Increasing Demand of J&J (Doxil/Caelyx)

J&J (Doxil/Caelyx) is helping in increasing the market growth. The high occurrence and mortality rate of ovarian cancer is one of the vital factors for this market. The increasing demand for Doxil or Caelyx as a second-line treatment for ovarian carcinoma is also projected to boost the demand in the coming few years. Thus, it boost the growth of the market.  

  • Increasing Product Launches

The launch of several products are creating much opportunities for the market growth. The increasing availability of products such as Nudoxa injections, Evacet, and DOXT SL tablets in the European region, is one of the essential factors driving the demand during the forecast period. Furthermore, the existence of numerous pipeline products that are awaiting approval by the U.S. FDA and European Medicines Agency is one of the major attributes of this market.

Restraints/Challenges

  • High Cost of Treatment Processes

The cost of treatment and the medications essential to reduce the tumor growth is extremely expensive. There are numerous drugs and injections that are of very high cost which in turn are hampering the growth of the market.

This liposomal doxorubicin market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the liposomal doxorubicin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Liposomal Doxorubicin Market       

The liposomal doxorubicin market were greatly affected as the COVID-19 pandemic caused havoc on healthcare systems globally, causing routine care to be disrupted in many hospitals and exposing cancer patients to extensive dangers. In 2021, according to a study titled "Impact of COVID-19 on cancer care in India: a cohort study," in which the researchers collected data on new patient registrations, hospital admissions, outpatient clinic visits, daycare admissions for chemotherapy, minor and major surgeries, patients receiving radiotherapy, and diagnostic tests. They found that the number of new patients registered reduced from 112 270 to 51 760. The data suggests that the demand for liposomal doxorubicin diminished due to COVID-19. The sales of also decreased as the patient's follow-up visits, hospital admissions, and outpatient chemotherapy was reduced due to COVID-19.

Global Liposomal Doxorubicin Market Scope

The liposomal doxorubicin market is segmented on the basis of product, type, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Formulation

Application

  • Bladder Cancer
  • Kaposi Sarcoma
  • Leukemia
  • Lymphoma
  • Breast Cancer
  • Others

Product

  •  Doxil
  •  Lipodox
  • Myocet
  • Others

Type

  • Anthracycline Antibiotic
  • Others

Route of Administration

  • Parenteral
  • Others

End-Users

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Liposomal Doxorubicin Market Regional Analysis/Insights

The liposomal doxorubicin market is analyzed and market size insights and trends are provided by product , type, route of administration, end-user, distribution channel as referenced above.

The major countries covered in the liposomal doxorubicin market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the increasing occurrences of sarcomas, breast, ovarian, and other cancers.

Asia-Pacific dominates the market because of high expenditure over healthcare sector and increasing technological advancements within the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Liposomal Doxorubicin Market Share Analysis

The liposomal doxorubicin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to liposomal doxorubicin market.

Key players operating in the liposomal doxorubicin market include:

  • Johnson & Johnson Services, Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Merck & Co., Inc. (U.S.)
  • Cipla Inc. (India)
  • Lupin (India)
  • Cadila Pharmaceuticals (India)
  • SRS Life Sciences (India)
  • Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd (China)


SKU-
Why Choose Us


Frequently Asked Questions

The Liposomal Doxorubicin Market is projected to grow at a CAGR of 5.90% during the forecast period by 2030.
The future market value of the Liposomal Doxorubicin Market is expected to reach USD 1961.50 million by 2030.
The major players in the Liposomal Doxorubicin Market are Johnson & Johnson Services, Inc.(U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Cipla Inc. (India), Lupin (India), Cadila Pharmaceuticals (India) and SRS Life Sciences (India), etc.
The countries covered in the Liposomal Doxorubicin Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, etc.